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Abstract
Introduction In nearly all cases, acromegaly is caused by
excess GH from a pituitary adenoma, resulting in elevated
circulating levels of GH and, subsequently, IGF-1. Treatment
goals are to eliminate morbidity and restore the increased
mortality to normal rates. Therapeutic strategies aim to
minimize tumor mass and normalize GH and IGF-1 levels.
Somatostatin analogues are the medical treatment of choice
in acromegaly, as first-line or post-surgical therapy, and have
proven efficacy in pituitary tumor volume reduction (TVR).
Methods Here we review the effects of somatostatin
analogue therapy on pituitary tumor volume in patients
with acromegaly.
Results TVRwith somatostatin analoguesmay bemediated
by direct anti-proliferative effects via activation of somato-
statin receptors, or by indirect effects, such as angiogenesis
inhibition, and is more pronounced when they are adminis-
tered as first-line therapy. Various studies of first-line treat-
ment with octreotide LAR have shown significant TVR in
C73 % of patients. First-line treatment with lanreotide
Autogel has shown evidence of TVR, although more studies
are needed. In a recent randomized, double-blind, 12-month
trial in 358 medical-treatment-naı¨ve acromegaly patients,
significant TVR was achieved by 81 % of patients adminis-
tered pasireotide LAR and 77 % administered octreotide
LAR. Pre-operative somatostatin analogue therapy may also
induce TVR and improve post-operative disease control
compared with surgery alone. TVR is progressive with pro-
longed treatment, and decreased IGF-1 levels may be its best
predictor, followed by age and degree of GH decrease.
However, TVR does not always correlate with degree of
biochemical control.
Conclusion Somatostatin analogues (first- or second-line
treatment) are the mainstay of medical therapy and, as first-
line medical therapy, are associated with significant pitu-
itary TVR in most patients.
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Introduction
The goals of treatment in acromegaly are to reduce mor-
bidity and to restore the increased mortality to normal age-
and sex-adjusted rates [1]. Therapeutic strategies are there-
fore aimed at removing tumor mass and/or stabilizing tumor
growth while maintaining pituitary function, as well as
normalizing the effects of growth hormone (GH) and insu-
lin-like growth factor 1 (IGF-1) at target tissues [2]. Plasma
levels of GH and/or IGF-1 are thereby controlled and any
bulk effects of the tumor removed or minimized. At present,
the main options for management of acromegaly are surgery
and medical therapy. Radiotherapy may be considered when
those options have failed. According to acromegaly treat-
ment guidelines, choice of initial therapy should be deter-
mined by individual patient characteristics [3]. Surgery is
still considered the first-line option for most patients, par-
ticularly when total tumor resection is feasible or relief of
optic chiasm compression is needed, and when an experi-
enced neurosurgeon is available, but some patients may be
more suited to first-line medical therapy [2].
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Surgical removal or debulking of the pituitary tumor is
usually performed via the transsphenoidal route. The
advantages of surgery include immediate lowering of GH
and, subsequently, IGF-1 levels, elimination of the local
mass effects of the tumor, and tissue sampling for analysis.
The chances of surgical success are best in patients with a
microadenoma (B10 mm diameter), enclosed macroade-
noma, and low pre-operative GH levels, and with highly
experienced specialist neurosurgeons [4–6]. Advances in
surgical instrumentation and imaging techniques have
helped to improve outcomes. Nevertheless, there remain a
number of potential complications of surgery, primarily
hypopituitarism, but also diabetes insipidus (usually tran-
sient), meningitis, and cerebrospinal leaks [6]. Furthermore,
only 40–70 % of patients who undergo surgical excision
achieve normalization of GH and IGF-1 levels [4–6].
Medical therapy
Since many patients have inadequately controlled disease
following surgery, subsequent medical therapy and/or
radiotherapy is often necessary. Although the use of medical
therapy has traditionally been limited to the adjuvant setting,
first-line treatment with pharmacological agents is appro-
priate in selected patients, including those with extrasellar
tumors, patients at risk of complications of anesthesia,
patients with severe complications of acromegaly, thosewho
refuse to undergo surgery, and patients wishing to retain
intact pituitary function [2, 3, 7–10]. Other patients may
benefit from pre-operative medical therapy to reduce tumor
size and improve clinical status before surgery, potentially
improving outcomes [11].
Somatostatin analogues
In healthy individuals, increased levels of GH stimulate the
release of somatostatin, which then suppresses secretion of
GH. In the presence of aGH-secreting pituitary tumor, plasma
GH levels are excessive and the normal regulatory feedback
loop fails. Cell-surface receptors for somatostatin have been
identified in a variety of tissues, including the pituitary, and
five subtypes have been characterized (designated sst1–5).
Approximately 90 % of GH-secreting pituitary tumors
express predominantly sst2 and sst5 [12]. The development of
somatostatin analogueswas a logical step towards themedical
management of acromegaly. Compared with endogenous
somatostatin, synthetic agents such as octreotide and lan-
reotide have much longer half-lives and are designed to bind
selectively to sst2 and, to a lesser extent, sst5.
The first-generation somatostatin analogues, octreotide
and lanreotide, are currently themedical treatment of choice in
acromegaly, as both adjuvant and first-line therapy, and have
demonstrated efficacy in controlling GH and IGF-1 levels
and in reducing pituitary tumor volume. Octreotide and lan-
reotide are both available in long-acting depot formulations
[octreotide long-acting repeatable (LAR) and lanreotide
Autogel]. Pasireotide LAR is a novel, second-generation
somatostatin analogue that has recentlybeen shown toprovide
superior biochemical control versus octreotide LAR in med-
ically naı¨ve patients and versus continued treatment with
octreotide LAR or lanreotide Autogel in inadequately con-
trolled patientswith acromegaly [13, 14]. The safety profile of
pasireotide is similar to that of the first-generation somato-
statin analogues, except for a higher frequency and degree of
hyperglycemia [13, 14]. Pasireotide-induced hyperglycemia
may be manageable with proactive monitoring and early
intervention.
Mechanisms of tumor volume reduction
with somatostatin analogues
Direct effects of first-generation somatostatin analogues
The anti-proliferative effects of somatostatin analogues in
pituitary adenomas may be mediated by somatostatin recep-
tors, activation of which can induce apoptosis, cell cycle
inhibition, and inhibition of growth factor effects [15, 16]. In
cancer models, for example, it has been demonstrated that
somatostatin analogues targeting sst1 and/or sst2 inhibit pla-
telet-derived growth factor (PDGF)-stimulated ERK activity,
with associated anti-proliferative effects [17]. Elsewhere, it
was shown that sst2 receptors may also be involved in
restoration of functional gap junctions (critical for mainte-
nance of the differentiated state) by inducing expression of
connexin [18]. The sst2 receptor has also been shown to exert
anti-oncogenic properties. Buscail and colleagues demon-
strated the loss of sst2 receptor expression in human pancreatic
carcinoma and showed that restoration of the sst2 gene defect
resulted in a significant reduction in cell growth and tumori-
genicity [19]. Animal models have also shown that re-ex-
pression of sst2 resulted in decreased tumor growth [20, 21].
The underlying mechanism for these direct effects has not
been fully elucidated, although certain pathways activated by
binding to the sst2 receptor havea known role inmediating cell
growth. Ligand interaction with sst2 initiates upregulation of
protein tyrosine phosphatase (PTP), a key modulator of
mitogenic effects that include cell differentiation and devel-
opment. SHP-1, a negative regulator of hematopoietic cell
signal transduction and negative regulator of cell signaling, is
dissociated after treatment with somatostatin or octreotide,
thereby dephosphorylating tyrosine kinase receptors [16, 22].
Additionally, sst2 activation has a role in modulating another
central regulator of cell growth, the MAPK pathway, includ-
ing phosphatidylinositol triphosphate kinases (PI3K) and Akt
phosphorylation [23].
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In a recent study using a pituitary tumor model includ-
ing GH-secreting pituitary cells, through upregulation of
the PI3K/Akt pathway, as well as mitogen-activated pro-
tein kinase pathways, octreotide increased both transcrip-
tion of the mixed lineage leukemia (MLL) gene and levels
of p27(Kip1), a protein that controls G1 cell cycle pro-
gression [24]. The authors concluded that the MLL–
p27(Kip1) pathway may be a novel therapeutic target in
pituitary tumors [24]. Additionally, a recent study evalu-
ated the anti-proliferative effect of octreotide in combina-
tion with an mTOR inhibitor in pituitary tumor cells, as
Akt activation reduces sensitivity to rapamycin and its
analogues and octreotide acts as an upstream inhibitor of
the PI3K/Akt pathway [25]. The study found that octreo-
tide decreased levels of activated Ser(473)-phosphorylated
Akt via modulating SHP-1, which, in combination with
rapamycin, led to increased levels of p27(Kip1), as well as
to macroscopic effects such as G1 cell cycle arrest [25].
In a pituitary cell model, it was shown that octreotide
exerts its anti-proliferative action by increasing expression
of the tumor suppressor gene Zac1 [26]. Zac1 is a recently
discovered novel zinc finger protein expressed in the
pituitary gland and brain that induces cell cycle arrest and
apoptosis [27, 28]. Octreotide was found to increase Zac1
levels by inhibiting the PI3K/Akt protein survival pathway,
thereby preventing phosphorylation of Zac1 [26]. The same
investigators subsequently demonstrated an association
between pituitary tumor Zac1 expression and response to
somatostatin analogue therapy in patients with acromegaly
[29].
Indirect effects of first-generation somatostatin analogues
Somatostatin analogues may also act indirectly by
inhibiting the release of growth factors and trophic hor-
mones (such as IGF-1 and insulin), or through inhibition of
angiogenesis, which limits tumor growth [15]. There is also
evidence that downregulation of vascular endothelial
growth factor (VEGF) may be how octreotide inhibits
angiogenesis in pituitary tumors [30]. In neuroendocrine
tumors, administration of octreotide significantly reduces
VEGF secretion (likely via the PI3K/Akt pathway) [31].
Clinically, the anti-angiogenic effect of octreotide has been
demonstrated in a small study of five patients with acro-
megaly, who showed a significant reduction in the func-
tional vascularity of their pituitary tumors after 24 weeks
of octreotide as first-line therapy [32].
Antiproliferative effects of pasireotide
Somatostatin analogues with different receptor binding pro-
files may also exert varying effects on cell growth. For
example, pasireotide, the multireceptor-targeted somatostatin
analogue, has approximately 30-, 11-, and 158-fold higher
functional activity than octreotide on sst1, sst3, and sst5,
respectively, and seven-fold lower activity on sst2 [33, 34].
Recent studies have shown that octreotide and pasireotide
stimulate distinct patterns of sst2A phosphorylation, with both
compounds internalizing the receptor upon binding, but with
pasireotide forming less stable beta-arrestin–sst2A complexes
compared with octreotide, leading to earlier recycling of
sst2A on the cell membrane [35]. Additionally, although an
adenylyl cyclase inhibitor like somatostatin, pasireotide has
an antagonistic effect on intracellular calcium stimulation
and ERK phosphorylation [36]. A previous study of pituitary
tumors had suggested that downregulation of phospho-ERK
(and upregulation of p27) is associated with sst-mediated
growth inhibition and that broader-spectrum somatostatin
analogues are likely to play an increasing role in tumor types
in which the MAPK pathway is over-expressed [37]. As a
recent immunohistochemical study showed that different
types of pituitary adenomas express a variety of sst, and that
in tumors isolated from patients with acromegaly, sst5 and
sst1 were more prevalent than sst2A, the authors concluded
that multireceptor somatostatin analogues may be a useful
approach, especially in somatotroph adenomas [38].
Adjuvant therapy with somatostatin analogues
A retrospective study of 86 patients showed that debulking
of tumors in patients poorly responsive to first-line therapy
with somatostatin analogues enhanced the success rate in
terms of achieving normal IGF-1 levels with post-surgical
subcutaneous (sc) octreotide, octreotide LAR, or lanreotide
Autogel [39]. All patients were treated with somatostatin
analogues before and after surgery for at least 6 months.
After the first course of treatment, pre-surgical magnetic
resonance imaging (MRI) showed no change in tumor size
in 49 %, mild volume reduction in 34 %, and moderate to
notable volume reduction in 13 % of patients; four patients
(5 %) had an increase in tumor size. After surgery, a
decrease in tumor size of[75 % was noted in 50 (58 %)
patients, of 50.1–75 % in 21 (24 %), of 25.1–50 % in 10
(12 %), and of\25 % in five (6 %). The success rate of
post-surgical somatostatin analogue therapy, in terms of
normalized IGF-1 and reduced GH levels, correlated with
the amount of tumor removed surgically. There was no
change in the cumulative prevalence of pituitary deficiency
during the study [39].
In a meta-analysis of published studies enrolling patients
with acromegaly to receive long-acting somatostatin ana-
logues for at least 3 months’ duration, adjuvant treatment
with octreotide LAR achieved GH levels \2.5 lg/L in
57 % of patients and normal IGF-1 in 67 % [40]. After a
mean [standard deviation (SD)] treatment duration of 17.9
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(1.5) months for all patients included in the meta-analysis,
the percentage achieving[10 % tumor volume reduction
was significantly higher with adjuvant octreotide LAR than
with adjuvant lanreotide sustained release (SR; 47 vs 21 %,
P\ 0.0001) [40].
Long-term (40 months) adjuvant therapy with octreotide
LAR has been shown to reduce GH and IGF-1 levels, and
reduce tumor volume, in patients with persistent and poorly
controlled acromegaly after transsphenoidal surgery,
adjuvant radiation, and/or dopamine agonists, but without
prior treatment with somatostatin analogues [41]. In this
study, 33 patients were treated with octreotide LAR 20 mg
every 28 days for 3 months, followed by individualized
dose titration to achieve adequate control of IGF-1 and GH
levels. Twenty-six patients were evaluable for tumor vol-
ume reduction at the 40-month time point. Tumor volume
fell from a median [interquartile range (IQR)] of 1.18
(0.08–3.50) mL at baseline to 0.21 (0–2.1) mL at
40 months (P = 0.08), as measured by MRI.
In a review of five studies, including 79 patients treated
with octreotide LAR as adjuvant therapy, 22 patients
(28 %) achieved significant ([20 or[25 %) tumor volume
reduction [42]. Octreotide LAR dosages in these studies
ranged from 10 to 40 mg every 28 days, over a duration of
6–30 months.
In the same review, two studies showed that lanreotide
SR adjuvant therapy achieved [20 % tumor volume
reduction in eight of 87 (9 %) patients [42]. These included
3/3 patients treated with lanreotide SR 60 mg every
21–28 days for 6 months, but only 5/84 (6 %) patients
treated with lanreotide SR 30 mg every 10–14 days for
24 months. A recent systematic review reported tumor
volume reduction in 9–42 % of patients treated with lan-
reotide SR who had previously undergone surgery, radio-
therapy, or treatment with drugs other than lanreotide [43].
Data from two recent studies showed a positive corre-
lation between sst2 receptor expression in pituitary ade-
nomas and both degree of tumor volume reduction and
biochemical response with octreotide LAR adjuvant ther-
apy [44, 45]. This may help to identify patients most likely
to respond to first-generation somatostatin analogues,
having failed to achieve adequate control with surgery
alone.
First-line therapy with somatostatin analogues
An overview of published studies evaluating somatostatin
analogues as first-line therapy showed that 6–24 months of
octreotide LAR therapy achieved significant ([20–30 %)
tumor volume reduction in 73–85 % of patients, with an
overall mean reduction in tumor volume of 35–68 %
(Table 1) [13, 46–54].
The beneficial effects of long-term octreotide LAR
treatment on tumor control were demonstrated in a study in
which the drug was administered as first-line therapy for a
median follow-up period of 48 months (range 6–108) [50].
Sixty-seven patients with acromegaly were enrolled in the
study and started on octreotide LAR 20 mg every 28 days
for 3 months, followed by individually titrated therapy.
Overall, 82 % of patients achieved [25 % reduction in
tumor volume, 44 % had[75 % reduction in tumor vol-
ume, and three patients had complete disappearance of
their tumor [50]. Overall, mean (SD) tumor volume
decreased significantly, from 2101 (2912) mm3 to 1010
(2196) mm3 (P\ 0.0001), and none of the patients had
any progression of tumor growth. The effects of octreotide
LAR on tumor volume reduction were similar in patients
with microadenomas, macroadenomas, and invasive ade-
nomas (Fig. 1).
However, even a shorter duration of octreotide LAR as
first-line therapy can be effective for reducing pituitary
tumor volume. In a prospective, multicenter study of 98
patients treated with octreotide LAR 10–30 mg every
4 weeks,[20 % tumor volume reduction was reported in
63 % of patients after 24 weeks, and in 75 % at 48 weeks
[51]. In this study, the greatest reductions in volume were
observed with microadenomas. Furthermore, in a retro-
spective study of 67 patients, tumor volume reduction was
observed as early as 3 months after starting octreotide LAR
therapy, with a mean (SD) overall tumor volume reduction
of 25.9 % (18.5 %) [53]. A significantly greater percentage
of patients with microadenomas or enclosed macroadeno-
mas achieved[25 % tumor volume reduction at 3 months
than those with extrasellar and invasive macroadenomas
(72.7 vs 35.6 %, P = 0.0009).
It has also been shown that tumor shrinkage progresses
with time (Fig. 2), even if, after 3 years of continuous
treatment, only minimal further effects on tumor volume
were seen [55]. The largest decreases in tumor volume
generally occurred in the first year of treatment.
Compared with octreotide LAR, there are less data on
lanreotide SR [56–58] or Autogel [59–61] on tumor vol-
ume reduction in the primary therapy setting. First-line
therapy with lanreotide SR for 1–48 months was reported
to achieve significant ([20–25 %) tumor volume reduction
in 22–50 % of patients, whereas a 1-year study in which 26
newly diagnosed patients were treated with titrated lan-
reotide Autogel for 12 months reported [25 % tumor
volume reduction in 77 % of patients, with a mean
reduction in tumor volume of 48 % (Table 1). In a recent
multicenter study of lanreotide Autogel 120 mg, 63 % of
90 patients had tumor volume reduction C20 % at
48 weeks (or the last available post-baseline value); 54 %
had achieved clinically significant tumor volume reduction
by week 12 [61]. A systematic review of the effects of
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Patients with significant tumor
volume reduction (definition of
significant) (%)
Octreotide LAR
Colao et al. [46] 15 12–24 months 73 53 53 80 ([20 %)
Ayuk et al. [47] 25 48 weeks 62 64 NR NR
Jallad et al. [48] 28 6–24 months NR 43 NR 76 ([25 %)
Colao et al. [49] 34 6 months 61 45.5 54a 74 ([30 %)
Cozzi et al. [50] 67 6–108 months 69 70 62 82 ([25 %)
Mercado et al. [51] 68 48 weeks 44 34 39 75 ([20 %)
Colao et al. [52] 56 24 months 86 84 68 NR
Colao et al. [53] 67 12 months 52 58 49 85 ([25 %)
Colao et al. [54] 40 48 weeks NR NR 35 73 ([20 %)
Colao et al. [13] 182 12 months 52 24 38 77 (C20 %)
Lanreotide SR
Baldelli et al. [56] 23 24 months 78 70 NR 22 ([20 %)
Attanasio et al. [57] 30 6–48 months 63 65 NR 50 ([25 %)
Lucas et al. [58] 104 1–[3 months 25 NR 29 ([20 %)
Lanreotide Autogel
Colao et al. [59] 26 12 months 58 58 48 77 ([25 %)
Annamalai et al. [60] 30 6 months 60 40 39a 79 (C20 %)
Caron et al. [61] 90 48 weeks 78 50 27 63 (C20 %)
Pasireotide LAR
Colao et al. [13] 176 12 months 48 39 40 81 (C20 %)
Gadelha et al. [14] 130 6 months 35/43b 25/26b 14/10b 19/11b ([25 %)
NR not reported
a Median tumor volume reduction
b Data shown for 40/60 mg doses
Fig. 1 Tumor size before and
during first-line octreotide LAR
treatment, evaluated in the
whole series and according to
tumor type [50]. Republished
with permission of The
Endocrine Society, from Cozzi
et al. [50]; permission conveyed
through Copyright Clearance
Center, Inc. *P\ 0.05
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lanreotide SR and Autogel on tumor mass showed that
tumor volume reduction occurred more frequently among
patients who received lanreotide as first-line therapy than
in patients who had already been treated with surgery,
radiotherapy, or other drugs [43].
Predictors of tumor volume reduction with first-line
somatostatin analogues
In the retrospective study by Colao et al. described above
[53], the investigators found that tumor volume reduction at
12 months was predicted by both decrease in GH level and
tumor volume reduction at 3 months, as long as octreotide
LAR was titrated according to individual requirements. The
percentage of patients with[25 % tumor volume reduction
increased significantly from months 3 to 12 in those with
extrasellar and invasive macroadenomas (from 35.6 % at
month 3 to 82.2 % at month 12, P\ 0.0001), as well as in
those with microadenomas or enclosed macroadenomas
(from 72.7 % at month 3 to 90.0 % at 12 months, P = 0.24).
In this analysis, no correlation was found between tumor
volume reduction and gender, age, baseline GH levels, or
Fig. 2 Progressive tumor
volume changes with octreotide
LAR in a women and b men.
The inset graphs indicate
percentage tumor volume
reduction on a yearly basis and
total volume change after
5 years [55]. Republished with
permission of The Endocrine
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baseline tumor volume. Conversely, a prospective study in
99 patients showed that primary therapy with depot
somatostatin analogues was associated with different degrees
of tumor shrinkage in 75.5 % of patients with acromegaly
[62]. IGF-1 levels after treatment were the best predictors of
tumor shrinkage, followed by GH levels and age [62].
In the long-term study by Cozzi et al. [50] in which
patients received octreotide LAR for up to 9 years, the
greatest tumor volume reduction was observed in patients
with higher baseline GH values, in those with the greatest
changes in GH and IGF-1 during treatment, and in patients
with macroadenomas (versus microadenomas; 81 vs 53 %,
P = 0.0196).
A review of data from published studies of all the
somatostatin analogues suggested that tumor volume reduc-
tion is progressive with prolonged treatment, and that
decreased IGF-1 levels are the best predictor of tumor volume
reduction, followed by age and degree of GH decrease [63].
Elsewhere, however, it has been observed that tumor volume
reduction does not necessarily correlate with the degree of
biochemical control [2, 42, 43]. As reported in a review dis-
cussing resistance to somatostatin analogues in patients with
acromegaly, the concepts of ‘biochemical resistance’ and
‘tumor resistance’ (volume increase or \20 % volume
reduction compared with baseline) should both be considered
before a patient is determined to be unresponsive to somato-
statin analogues, as significant tumor volume reduction has
been achieved in the absence of complete biochemical control
in certain patients [64]. The authors of a different recent
review suggested that this dissociation may be explained by
the hypothesized direct effects of somatostatin analogues on
tumor tissue, the different mechanisms underlying their anti-
mitotic and anti-secretory effects, and indirect effects such as
anti-angiogenesis [43]. Indeed, the receptor signaling path-
ways that mediate the anti-proliferative effects of somato-
statin analogues are usually different from those involved in
the anti-secretory effects of these agents.
Furthermore, the relative prevalence of different receptor
subtypes on the pituitary adenoma may affect outcome. In
one case report, a patient with a large intra- and extrasellar
macroadenoma was found to have a 50 % reduction in tumor
size after 5 months of octreotide LAR, despite a failure to
normalize IGF-1 and GH levels [65]. Subsequent resection
and analysis of the tumor tissue revealed higher expression of
the sst5 receptor compared with sst2, which the authors
suggested may account for the lack of biochemical effect.
Further studies are needed to clarify the precise effects of
somatostatin analogue therapy in different patients.
Pre-operative somatostatin analogue therapy
In general, pre-operative therapy with somatostatin ana-
logues has been shown to have a beneficial effect on tumor
size. For example, two non-randomized studies performed
in the 1990s showed that the use of pre-operative octreotide
achieved tumor volume reduction and softening of the
tumor, facilitating subsequent tumor removal by surgery
[66, 67]. In the first of these studies [66], octreotide was
administered to 22 patients at doses of 150–600 lg/day for
3–6 months before surgery. Significant tumor volume
reduction (C30 %) was documented in five patients, and all
22 had significant reductions in GH and IGF-1 levels [66].
In the second study [67], 64 patients received octreotide
300–1500 lg/day for periods ranging from 3 to 9 weeks
(n = 14, group 1) and from 3 to 39 months (n = 50, group
2). The investigators reported tumor volume reduction in
60 % of patients within 3 weeks, which was nearly maxi-
mal by 3–4 months. A greater number of patients in group
2 achieved [25 % tumor volume reduction (14 of 48
evaluable vs 1 of 14 in group 1). In both studies, pre-
treatment with octreotide also improved the clinical status
of patients prior to surgery and resulted in significantly
better post-operative biochemical control compared with
patients not pre-treated. A third uncontrolled study later
performed in 90 patients with acromegaly found that pre-
treatment with octreotide sc (mean daily dose 221 lg) for
at least 3 months slightly improved the rate of biochemical
control in patients with an invasive but potentially resect-
able macroadenoma [68]. During pre-treatment with
octreotide sc, 31 % of patients achieved an MRI-confirmed
reduction in tumor volume. Additionally, patients who
received pre-operative treatment with octreotide sc were
more likely to present to surgery with pituitary adenomas
fluid or soft in texture, as well as white or gray in color,
compared with patients who did not receive pre-operative
octreotide [68].
In contrast, a small, randomized, controlled study in
which octreotide was administered at a mean (SD) daily
dosage of 470 (160) lg for a mean (SD) duration of 16.5
(10) weeks found that a non-significant reduction in tumor
volume was reported during pre-treatment [69].
The Pre-operative Octreotide Treatment of Acromegaly
(POTA) study was the first prospective, randomized trial
comparing the outcome of 6 months of octreotide LAR
pre-treatment with that of surgery alone [70]. The overall
results showed that post-surgical normalization of IGF-1
was achieved in 45 % of pre-treated patients, compared
with 23 % of patients who underwent direct surgery
(P = 0.11) [70]. Among patients with macroadenomas, the
difference in IGF-1 normalization was significantly in
favor of the group with octreotide pre-treatment (50 vs
16 %, P = 0.017). In contrast to previous studies, there
was no evidence of tumor softening with pre-operative
octreotide LAR; in fact, the investigators noted that tumor
firmness was common in this group. Furthermore, tumor
volume change during pre-treatment was similar in both
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cured and non-cured patients post-surgery. Further studies
are needed to clarify the effects of pre-operative octreotide
LAR on tumor volume and consistency.
Two studies have reported pre-operative use of lan-
reotide SR 30 mg for up to 3 months [58, 71]. In one
prospective, open-label study of 104 newly diagnosed
acromegalic patients, lanreotide SR resulted in at least
some tumor volume reduction in 66 %, and [20 %
reduction in 29 %, of patients [58]. In the other non-ran-
domized study, of 82 patients, tumor volume decreased
significantly during lanreotide SR therapy, from 5662 to
2326 mm3 (P\ 0.0001) [71]. This study also reported
softening of the tumor, making it easier to remove [71].
An article that reviewed all the published literature on
pre-operative somatostatin analogue therapy concluded
that it should be considered in all patients with GH-se-
creting macroadenomas (including invasive) when the
overall surgical remission rate for macroadenomas at the
treating center is\50 % [72]. When deemed appropriate,
somatostatin analogues should be given for 3–6 months
before surgery. Patients with minimally invasive
macroadenomas are most likely to benefit in terms of
improved surgical remission.
Pegvisomant
At present, pegvisomant is the only clinically available GH
receptor antagonist for the treatment of acromegaly. Rather
than inhibiting GH release, pegvisomant acts at the periph-
ery to block the effects of GH on target tissues. By binding
to GH receptors in the hepatocytes, pegvisomant blocks
IGF-1 production. Pegvisomant is currently indicated for the
treatment of patients who have had an inadequate response
to surgery, radiotherapy, and/or prior medical therapy, or for
those in whom such therapies are considered inappropriate.
It is effective at normalizing IGF-1 levels (67.5 % after
5 years of treatment [73]), and it may also improve insulin
resistance and cardiovascular risk parameters [74] and nor-
malize elevated markers of bone turnover [75].
In contrast to somatostatin analogues, pegvisomant has
not been shown to have an effect on tumor volume
reduction. In a small proportion of cases, pituitary tumors
have been shown to increase in size, including 30 (3.2 %)
of 936 patients registered in the ACROSTUDY database
with at least two MRI readings [76], and regular monitor-
ing is therefore recommended. In patients previously
treated with somatostatin analogues, it is possible that
discontinuing somatostatin analogues increases the risk of
tumor growth by removing the tumor-suppressive effects of
somatostatin analogue therapy. The addition of pegviso-
mant to somatostatin analogue therapy may allow further
reductions in IGF-1 and may also reduce the risk of tumor
volume increase [76–79].
Future therapies
Pasireotide is a novel, multireceptor-targeted somatostatin
analogue with high binding affinity for sst1,2,3 and sst5 that
has been approved for the treatment of Cushing’s disease
[80–82] and acromegaly [13, 14, 83, 84]. Based on the
differences in binding affinity and functional activity of
pasireotide and octreotide, it can be speculated that in cells
and tissues that express somatostatin receptor subtypes
other than sst2, pasireotide may have a stronger inhibitory
effect on hormone secretion and tumor growth than
octreotide [34, 85]. Results from a 3-month Phase II study
in patients with de novo or persistent/recurrent acromegaly
showed that 39 % of patients had [20 % reduction in
pituitary tumor volume after 3 months of treatment with
pasireotide, which increased to 54 % of patients after
6 months of treatment [83]. Moreover, it was demonstrated
in a large, Phase III randomized trial in patients with
medically naı¨ve acromegaly that pasireotide LAR and
octreotide LAR have a similar effect on tumor volume
reduction, despite the fact that pasireotide LAR was
superior to octreotide LAR in providing biochemical con-
trol (Table 1) [13]. After 12 months of treatment, 81 % of
pasireotide LAR patients had C20 % reduction in tumor
volume, compared with 77 % of octreotide LAR patients.
A recent study evaluated pasireotide LAR in patients with
long-standing, inadequately controlled acromegaly, all of
whom had received octreotide LAR 30 mg or lanreotide
Autogel 120 mg monotherapy for C6 months before
screening [14]. After 24 weeks of treatment, a greater
proportion of patients receiving pasireotide LAR 40 and
60 mg achieved tumor volume decrease of[25 % com-
pared with patients who continued receiving octreotide
LAR or lanreotide Autogel (18.5 and 10.8 vs 1.5 %,
respectively).
Limitations
There are limitations associated with measuring tumor
volume reduction during somatostatin analogue therapy.
For example, computed tomography and MRI performed
before the early 1990s had poor image resolution compared
with more modern imaging [42]. This may have led to
inaccurate estimation of the extent of tumor volume
reduction, which therefore means that it is difficult to
compare results across studies. More recently, standard
formulae [46, 56] or geometric approximations [86] have
commonly been used to estimate tumor volume; however,
these methods lack precision for larger, more irregularly
shaped tumors. There are also potential problems associ-
ated with observer subjectivity [42]. Recent studies have
used more rigorous methods to assess tumor volumes. For
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example, in the Phase III pasireotide study, tumor volume
was calculated by hand-drawing around the tumor cir-
cumference in coronal cross-sections, multiplying the area
by slice thickness, and summing the resulting volumes
across all slices containing tumor. Intra-observer variability
of the blinded central reader was assessed independently by
a third-party organization, and the results were found to be
consistent, reproducible and, in most cases, unaffected by
complex tumor anatomy [13]. In the PRIMARYS study,
tumor volumes were measured centrally by three neurora-
diologists blinded to the chronology of patients’ scans
through the use of pre-specified methods, including com-
puter modeling of tumor volumes, to ensure consistent and
unbiased measurements [61]. Along these lines, future
studies assessing tumor volume reduction with somato-
statin analogue therapy should use robust methodology and
follow the practices established in more recent trials.
Conclusions
Somatostatin analogues are associated with significant
pituitary tumor volume reduction in the majority of patients
when administered as first-line therapy, and the reduction
in tumor volume is progressive with prolonged treatment.
In addition, pre-operative therapy with somatostatin ana-
logues may be beneficial in some cases. The extent of
decrease in IGF-1 levels during treatment may be the best
predictor of tumor volume reduction, followed by age and
degree of GH decrease, although tumor volume reduction
does not always correlate with the degree of biochemical
control. In a minority of patients, significant tumor volume
reduction can be achieved with somatostatin analogues in
the absence of biochemical control.
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